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Abstract Lipoprotein lipase (LPL) acts independently of its
function as triglyceride hydrolase by stimulating macrophage
binding and uptake of native, oxidized and glycated LDL.
Peroxisome proliferator-activated receptors (PPARs) are nucle-
ar receptors expressed in monocyte/macrophages, where they
control cholesterol homeostasis. Here we study the role of
PPARs in the regulation of LPL expression and activity in
human monocytes and macrophages. Incubation of human
monocytes or macrophages with PPARK or PPARQ ligands
increases LPL mRNA and intracellular protein levels. By
contrast, PPAR activators decrease secreted LPL mass and
enzyme activity in differentiated macrophages. These actions of
PPAR activators are associated with a reduced uptake of
glycated LDL and could influence atherosclerosis development
associated with diabetes. ß 2002 Federation of European Mi-
crobiological Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Lipoprotein lipase (LPL) is a 58 kDa glycoprotein that
plays a central role in lipoprotein metabolism by hydrolyzing
triglycerides present in chylomicrons and very low density
lipoproteins (VLDLs). LPL, which acts as homodimeric en-
zyme requires apoCII as cofactor and is produced in a large
number of tissues [1]. In most tissues, LPL is synthesized by
the parenchymal cells and subsequently transferred to the en-
dothelial surface where, bound to heparan sulfate proteogly-
cans (HSPGs) [2], it exerts its activity. In the arterial wall,
LPL is expressed in macrophages and smooth muscle cells [2].
Through its enzymatic activity, LPL generates remnant
lipoprotein particles which are readily taken up by cells via
receptors recognizing apoE as ligand [3] and produces free
fatty acids and phospholipids [4]. Besides this activity, LPL
also acts as a bridging factor which enhances binding to the
extracellular matrix [5] and uptake of both native and oxi-
dized LDL by macrophages [6]. It has also been recently re-
ported that in macrophages and ¢broblasts, LPL is required
for the binding and internalization of glycated LDL
(glyLDL), via a pathway independent of the classical LDL
receptor pathway [7]. In addition, LPL promotes the adhesion
of monocytes to endothelial cells by binding to both monocyte
surface proteins and endothelium HSPGs [8]. Taken together
these observations indicate that LPL expressed in vascular
macrophages may exhibit pro-atherogenic activities.
Peroxisome proliferator-activated receptors (PPARs) are li-
gand-activated transcription factors which upon heterodimer-
ization with the 9-cis-retinoic acid receptor (RXR), bind to
speci¢c peroxisome proliferator response elements (PPREs),
thus regulating the expression of target genes involved in in-
tra- and extracellular lipid metabolism [9]. PPARs also regu-
late the expression of several genes implicated in the in£am-
matory response by interfering with the AP-1, STAT or
NFUB signaling pathways [9]. The natural prostaglandin 15-
deoxy-v12;14-prostaglandin J2 (15dPG-J2) and the synthetic
anti-diabetic glitazones are ligands for PPARQ, while hypoli-
pidemic ¢brates and eicosanoids such as leukotriene B4 and
8(S)-hydroxyeicosatetraenoic acid (8(S)-HETE) are synthetic
and natural ligands respectively for PPARK [9]. PPARK is
predominantly expressed in liver, heart, kidney and muscle
[10], while PPARQ is adipose tissue speci¢c, where it triggers
adipocyte di¡erentiation and lipid storage [11,12]. PPARK is
expressed in human monocytes and in fully di¡erentiated
macrophages, while PPARQ is exclusively expressed in cells
undergoing di¡erentiation into macrophages [13]. In addition,
both PPARK and PPARQ are also detected in macrophage-
rich areas of human atherosclerotic lesions [14^16]. In macro-
phages, PPARs inhibit in£ammatory cytokine-induced activa-
tion [17], promote apoptosis [13] and control lipid homeosta-
sis through their e¡ects on the expression of several key genes
including SR-A, CD36, SR-BI and ABCA1 [16,18^20].
Since both LPL and PPARs are expressed in macrophages,
and since PPARK and PPARQ regulate the expression of LPL
in liver and adipose tissue, respectively [21], the goal of this
study was to investigate the role of PPARs in LPL gene reg-
ulation in human monocytes and in fully di¡erentiated macro-
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phages. Our results show that LPL expression is upregulated
by PPAR activators in human monocytes as well as in di¡er-
entiated macrophages. However, unexpectedly, the amounts
of secreted LPL are reduced after treatment with PPAR acti-
vators, an e¡ect which is accompanied by a decrease in LPL
enzyme activity. Lowered LPL secretion is accompanied by a
reduced uptake of glycated LDL, which may contribute to the
bene¢cial e¡ects of PPAR agonists on macrovascular disease
in diabetes.
2. Materials and methods
2.1. Cell culture
Mononuclear cells were isolated from blood of healthy normolipi-
demic donors by Ficoll gradient centrifugation and cultured as de-
scribed [13]. Mature monocyte-derived macrophages were used for
experiments after 10 days of culture, whereas experiments in mono-
cytes were done using cells isolated after 45 min of adherence to the
plastic dishes. For treatment, medium was changed to RPMI 1640
with 1% Nutridoma HU (Boehringer, Mannheim, Germany) contain-
ing di¡erent activators. Heparin (Choay) (10 U/ml) was added for 24 h
at the same time as the activators.
2.2. Isolation of total RNA and Northern blot analysis
After 6 h incubation with the indicated PPAR activators, cells were
washed with PBS and used for RNA extraction using the RNA plus
kit (Bioprobe System, Montreuil, France). For Northern blot analysis,
membranes were hybridized with [32P] random prime labeled human
LPL [22] or 36B4 control cDNA probes.
2.3. Protein extraction and Western blot analysis
Cells were harvested in ice-cold lysis bu¡er containing PBS, 1%
Triton X-100, and protease inhibitor mixture (ICN, Orsay, France)
to which 1 mM phenylmethylsulfonyl £uoride (PMSF) was added.
Western blot analysis was performed using rabbit polyclonal antibod-
ies raised against human LPL (amino acids 253^274) or goat poly-
clonal antibody against L-actin (Santa Cruz) as internal control. Syn-
thetic peptides of LPL (amino acids 253^274) were produced by the
classical solid phase synthesis as described by Merri¢eld [23].
2.4. Quanti¢cation of LPL secretion by human macrophages using
enzyme-linked immunosorbent assay (ELISA)
LPL mass in culture media was measured by ELISA. After incu-
bation with an anti-LPL polyclonal antibody (chicken IgG, 5 Wg/ml in
5 ml PBS, 100 Wl/well) for 24 h at 37‡C, plates were washed with PBS.
Macrophage culture media and a puri¢ed human LPL standard (0^40
ng protein/ml) were diluted in 1% BSA^PBS (w/v) and 100 Wl was
added to each well and incubated overnight at 4‡C. Plates were
washed and incubated with the mouse monoclonal antibody mAb
5D2 for 3 h at room temperature. After additional washing, 100 Wl
of anti-mouse peroxidase-conjugated IgG was incubated for 2 h at
room temperature. After rinsing, development was carried out with
phenylenediamine dihydrochloride (OPD, Dako, Carpinteria, CA,
USA) substrate. Using this ELISA technique, both monomer and
dimer forms of LPL are detected. Each experiment was performed
in triplicate and each triplicate was quanti¢ed at three di¡erent dilu-
tions.
2.5. LPL catalytic activity assays
LPL was measured in the medium after release by heparin (10 U/
ml) as described [24]. LPL catalytic activity was measured using an
emulsi¢ed [3H]triolein substrate [25]. After incubation of 50^100 Wl of
sample with 100 Wl of substrate for 60 min, released [3H]-fatty acids
were separated from the reaction mixture using the method of Bel-
frage and Vaughan [26]. LPL activity is expressed in mU which cor-
responds to nmol of fatty acids released per min.
2.6. LDL glycation and acetylation
LDL (1 mg protein per ml) in 10 mM PBS, pH 7.4 containing
0.01% EDTA, 25 WM butylhydroxytoluene (BHT), 50 WM diethylene-
triaminepentaacetic acid (DTPA), 12 mg/ml sodium cyanoborohy-
dride and 40 mmol/l glucose was ¢lter-sterilized and incubated at
37‡C for 6 days under nitrogen. LDL samples were extensively dia-
lyzed against PBS containing 0.01% EDTA. The amount of glycation
was estimated by measuring free NH2 residues by £uorescamine £uo-
rescence. 20 Wl of control or glycated LDL (1 mg of protein/ml) was
added to 730 Wl of borate bu¡er (200 mM, pH 8.5) and mixed while
250 Wl of £uorescamine (539 WM in acetone) was added. Following
incubation at room temperature for 1 h, £uorescence was measured at
475 nm using an excitation wavelength of 390 nm. The £uorescence of
treated samples is expressed as percentage of the control sample. To
control the integrity of tryptophan residues of apoB, the decrease of
the tryptophan £uorescence was measured at 331 nm using an exci-
tation wavelength of 282 nm [27].
Acetylation of LDL was performed as described [28].
2.7. Cholesterol loading experiments
10 days old human macrophages were cholesterol loaded by incu-
bation with glycated or acetylated LDL (50 Wg/ml, containing or not
[3H]cholesterol) [28] in RPMI 1640 medium supplemented with 1%
Nutridoma for 48 h. The PPAR activators rosiglitazone 100 nM and
Wy14643 50 WM were added to the culture medium 24 h before
cholesterol loading and thereafter every 24 h. After this incubation
period, cells were washed in PBS and intracellular lipids were ex-
tracted in hexane/isopropanol, dried under nitrogen and total choles-
terol subsequently measured by enzymatic assays (Boehringer). In the
same experiments, [3H]cholesterol radioactivity was measured by scin-
tillation counting in cellular lipids extracted with hexane/isopropanol.
Cellular proteins were collected by digestion in NaOH and measured
by the Bradford assay (Bio-Rad).
3. Results
3.1. PPAR activators induce LPL expression in
human monocytes
Since PPAR agonists have been shown to regulate LPL
expression in liver and adipose tissue, we investigated whether
PPAR activation in human monocytes in£uences LPL expres-
sion. Monocytes isolated by 45 min of cell adhesion to culture
dishes were incubated with several PPARK and PPARQ ago-
Fig. 1. PPAR activators induce the expression of LPL in human
monocytes. Monocytes isolated by 45 min of adhesion to the culture
dish, were treated with DMSO (control), Wy14643 (20 WM), rosigli-
tazone (50 nM) and GW2331 (1 WM) for 24 h. Total cellular pro-
tein extracts (25 Wg) were used for Western blot analysis as de-
scribed in Section 2. a: Western blot picture. b: Quanti¢cation by
optical densitometry of LPL protein bands after normalization to
L-actin levels. Results of two independent experiments on di¡erent
monocyte preparations are shown.
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nists during 24 h. Western blot analysis (Fig. 1) showed that
LPL protein is slightly expressed in control cells (DMSO).
Treatment of cells with the PPARK ligand Wy14643 at low
concentration (20 WM), resulted in an approximately 2-fold
induction of LPL protein levels. Treatment with the highly
speci¢c PPARQ activator rosiglitazone (50 nM) at a concen-
tration activating PPARQ transcription activity without a¡ect-
ing cell viability [13], was without major e¡ect on LPL protein
levels, likely due to the low amounts of PPARQ expressed in
cells at this step of di¡erentiation [13]. Addition of the mixed
PPAR agonist GW2331 (EC50 = 50 nM for hPPARK and 300
nM for hPPARQ) at concentrations of 1 WM activating both
PPARK and PPARQ, increased LPL expression about 4-fold.
3.2. PPAR activators induce LPL expression in di¡erentiated
human macrophages
Since PPARs have been shown to activate LPL gene ex-
pression at the transcriptional level via a PPRE in its pro-
moter [21], the in£uence of PPAR agonists on LPL gene ex-
pression in human macrophages was evaluated. Northern blot
analysis of RNA extracted from di¡erentiated macrophages
incubated for 6 h with PPAR ligands was performed. A spe-
ci¢c signal with the size of human LPL mRNA [22] was de-
tected in these macrophages (Fig. 2a). Furthermore, LPL
mRNA was induced by all PPAR agonists tested (Fig. 2a).
The average relative increase of LPL mRNA normalized to
control 36B4 mRNA levels, as determined by two indepen-
dent experiments on di¡erent macrophage preparations, was
approximately 3-, 4-, 3-, and 3.4-fold for rosiglitazone
(50 nM), Wy14643 (20 WM), GW2331 (200 nM) and PG-J2
(1 WM), respectively (Fig. 2a). To determine whether the in-
duction of LPL mRNA expression by PPAR activators in
macrophages resulted in an increase of intracellular LPL pro-
tein levels, Western blot analysis of total cellular proteins was
performed. A marked induction of LPL protein level was
observed in cells treated during 24 h with all di¡erent
PPAR activators tested (Fig. 2b). The increase of the protein
expression levels was estimated by densitometric analysis of
two independent experiments to be about 1.4-, 2.3-, 1.5-, and
2.8-fold for rosiglitazone (50 nM), Wy14643 (20 WM),
GW2331 (200 nM), PG-J2 (1 WM), respectively (Fig. 2b).
Furthermore, the e¡ect of GW2331 on LPL induction was
weaker than in Fig. 1, since the compound was added at lower
concentration. No signi¢cant variation in L-actin expression
Fig. 2. PPAR activators induce LPL expression in human di¡erentiated macrophages. 10 days old human macrophages were treated for 6 h
(for RNA analysis) or for 24 h (for protein analysis) with DMSO (control), Wy14643 (20 WM), rosiglitazone (50 nM), GW2331 (200 nM) and
PG-J2 (1 WM). a: Northern blot analysis was performed with 10 Wg of total RNA as described under Section 2. Autoradiograph of the North-
ern blot and quanti¢cation by optical densitometry of LPL mRNA levels: values are normalized to internal control 36B4 mRNA and levels
are expressed relative to DMSO treated cells set as 1. b: Western blot of intracellular protein levels (25 Wg of total cellular proteins). Quanti¢-
cation by optical densitometry of LPL protein bands was performed and values are normalized to L-actin levels and expressed relative to ve-
hicle treated control cells set as 1. Results presented are from experiments performed on two independent cell preparations.
Fig. 3. PPAR activators decrease secretion of LPL in human di¡er-
entiated macrophages. 10 days old di¡erentiated macrophages were
treated with DMSO (control), Wy14643 (20 WM), rosiglitazone
(50 nM) and GW2331 (200 nM) after addition of heparin to stabi-
lize LPL. Amounts of secreted LPL were determined by ELISA as
described. Results are the mean þ S.E.M. of triplicate determina-
tions, representative of four independent experiments. Statistically
signi¢cant di¡erences between treatments are indicated
(***P6 0.001 and *P6 0.05 vs. DMSO, as determined by ANOVA
followed by Mann^Whitney’s test).
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was observed between control and treated macrophages (Fig.
2b).
3.3. PPAR activators decrease LPL secretion and activity in
human di¡erentiated macrophages
To evaluate whether PPARK and PPARQ activators induce
LPL secretion by di¡erentiated macrophages, ELISA of LPL
levels was performed on culture media. Treatment of di¡er-
entiated macrophages with PPARK ligands (Wy14643: 20 WM
and GW2331: 200 nM) or PPARQ ligand rosiglitazone (50
nM) results in decreased amounts of extracellular enzyme
mass (Fig. 3).
Moreover, LPL enzyme activity was markedly reduced by
treatment with PPAR activators (Fig. 4) dropping to 53 and
67% of control for Wy14643 (20 WM) and rosiglitazone
(50 nM), respectively. In the same experiments, incubation
with GW2331 (200 nM) and PG-J2 (1 WM) showed a reduc-
tion of LPL activity by 52 and 44%, respectively. These e¡ects
were not due to a chemical inhibition of LPL activity by the
PPAR activators since incubation of puri¢ed LPL with these
compounds did not alter its enzymatic activity (data not
shown).
3.4. PPAR activators decrease uptake of glycated LDL in
human di¡erentiated macrophages
To determine the physiological consequences of inhibition
of LPL secretion by PPARs in human macrophages, the ef-
fects of PPAR ligands on the uptake of glyLDL, which are
characterized by glycation of lysine residues of apoB and tak-
en up by macrophages through an LPL-dependent mechanism
were studied [7]. Treatment with either the PPARK ligand
Wy14643 or the PPARQ ligand rosiglitazone added 24 h be-
fore cholesterol loading and thereafter every 24 h, decreased
cholesterol accumulation from glyLDL in these cells (Fig. 5a).
In order to demonstrate that the variation of intracellular
lipids was not due to the action of PPAR ligands on de
novo cholesterol synthesis, human macrophages were loaded
with [3H]cholesterol-containing glyLDL and the amounts of
[3H]cholesterol were evaluated by scintillation counting of cel-
lular lipid extracts. Wy14643 (50 WM) and rosiglitazone
(100 nM) decreased cellular [3H]cholesterol amounts, com-
pared to solvent treated cells (Fig. 5b). As a control, PPARK
and PPARQ activators did not in£uence cholesterol accumu-
lation in di¡erentiated macrophages incubated and treated
under the same conditions with acetylated LDL (data not
shown). These results indicate that through their actions on
LPL regulation, PPAR activation decreases the uptake of
glyLDL.
Fig. 4. PPAR activators decrease LPL enzyme activity in human
macrophages. 10 days old macrophages were treated for 24 h with
DMSO (control), Wy14643 (20 WM), rosiglitazone (50 nM), PG-J2
(1 WM) and GW2331 (200 nM) in the presence of heparin to stabi-
lize LPL. Extracellular LPL activity measurement was performed as
described. Results are the mean þ S.E.M. of triplicate determina-
tions, representative of four independent experiments. *P6 0.05 vs.
DMSO, as determined by ANOVA followed by Mann^Whitney’s
test.
Fig. 5. PPAR activators reduce uptake of glycated LDL by di¡erentiated human macrophages. Di¡erentiated macrophages were incubated for
48 h with 50 Wg/ml of [3H]cholesterol-containing glyLDL. Wy14643 (50 WM) or rosiglitazone (100 nM) were added 24 h before cholesterol
loading and thereafter every 24 h. a: Intracellular total cholesterol was enzymatically determined. b: Intracellular [3H]cholesterol was deter-
mined by scintillation counting. Results are the mean þ S.E.M. of triplicate determinations. ***P6 0.001 and *P6 0.05 vs. DMSO, as deter-
mined by ANOVA followed by Mann^Whitney’s test.
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4. Discussion
Lipid-loaded foam cells, derived principally from mono-
cyte-derived macrophages, are a characteristic feature of ath-
erosclerotic lesions [29]. The transformation of macrophages
into foam cells, which is a consequence of cellular uptake of
lipids from oxidized LDL and triglyceride-rich lipoproteins
and their remnants [30^33], is thought to be an initial step
in fatty streak and atherosclerotic lesion formation. Lipid
capture by macrophages is mediated by a number of receptors
including scavenger receptors [34,35], LDL receptors [36,37],
VLDL and TG-rich lipoprotein (TRL) receptors [38], as well
as by the interaction and retention of lipoproteins by proteo-
glycans on the cell surface and by the extracellular matrix.
LPL is implicated in the generation of TRL remnants and
in their subsequent uptake by macrophages and may thus
play a role in the formation of foam cells [39^42]. In addition,
a requirement for LPL in the uptake of glycated LDL by
macrophages, independently of the LDL receptor pathway,
has been recently demonstrated [7].
It is therefore of considerable importance to identify the
factors which control LPL expression in atherosclerotic lesion
macrophages. Increasing lines of evidence implicate transcrip-
tion factors of the PPAR family in the regulation of macro-
phage function and in the control of their transformation into
foam cells. Although PPARK and PPARQ have been shown to
regulate the expression of the LPL gene in liver and adipo-
cytes respectively [21,43,44], it remained to be determined
whether PPAR activators also regulate LPL expression in
vascular wall macrophages.
In the present study and for the ¢rst time using a model of
human monocyte/macrophages, we demonstrate that PPARK
and PPARQ activators increase LPL expression. In primary
human monocytes, PPARK activation resulted in the induc-
tion of LPL expression. By contrast, addition of the PPARQ
ligand rosiglitazone did not in£uence LPL expression. This
result is in line with our previous observations that human
monocytes express low levels of PPARQ at this step of the
di¡erentiation process [13]. In human di¡erentiated macro-
phages the induction of LPL protein expression levels was
observed after treatment with both PPARK and PPARQ li-
gands, which was associated with increased LPL mRNA lev-
els, in agreement with the presence of high levels of PPARK
and PPARQ expression in these cells. These results suggest
that PPARK and PPARQ activators upregulate LPL expres-
sion in human monocytes and macrophages through a tran-
scriptional mechanism. These conclusions are supported by
previous data [21], demonstrating that PPARK and PPARQ
ligands induce the expression of LPL in liver and adipocytes
respectively via PPAR binding to PPRE site localized at se-
quences 3169 to 3157 of the human LPL gene promoter [21].
Although it cannot be excluded that increased LPL mRNA
stability also occurs, it appears likely that the regulation of
LPL by PPAR agonists in monocytes and macrophages oc-
curs via this positive PPRE. Our data add LPL to the list of
genes which are upregulated by PPARs through a PPRE-de-
pendent mechanism in macrophages such as CD36/FAT, a
scavenger receptor class B family member and fatty acid
transporter [19].
Surprisingly, the increase of LPL gene expression by PPARK
and PPARQ agonists is accompanied by a decrease in the mass
of LPL secreted by human macrophages as well as lowered
extracellular LPL enzyme activity. Although the mechanism
of reduced LPL secretion by PPARs is unknown, PPAR acti-
vators may cause an inhibition of cellular LPL tra⁄cking
resulting in the reduced secretion of LPL. A similar reduction
of LPL activity after rosiglitazone treatment was also ob-
served in the 3T3-F442A and 3T3-L1 adipocyte cell lines
[45]. These authors furthermore demonstrated that the re-
duced LPL activity was not due to a chemical inhibition of
LPL activity by PPAR activator molecules [45]. In the same
line, we could not detect an inhibition of LPL activity by
PPAR activation in our LPL lipolysis assays.
Furthermore, our results on the e¡ects of PPAR on reduc-
tion of macrophage LPL secretion and activity appear in con-
trast with previous observations published while this work
was in progress [46], demonstrating an increase of extra-
and intracellular LPL mass and activity in murine J774 mac-
rophages after treatment with natural fatty acid-derived
PPAR activators, such as palmitic acid, stearic acid and lino-
leic acid [46]. Even the reasons for these discrepancies are still
not clear understood, one possible explanation could be that
activated PPARs regulate LPL expression and activity in a
species-speci¢c manner. In addition, natural and synthetic
PPAR ligands could have distinct e¡ects on LPL regulation,
which may be due to the low speci¢city of natural activators
compared to the more selective synthetic compounds used in
our study. Regulation of macrophage LPL by fatty acids
(FAs) may involve other transcription factors such as FA-
activated receptor (FFAR) which could recognize the putative
PPRE sequence present in the LPL gene. Moreover, FAs
could stimulate protein kinase C (PKC) which plays a key
role in the regulation of LPL gene [46]. By contrast, in an-
other study using adult rat cardiomyocytes, two synthetic
PPARK ligands (Wy14643 and BM-17.0744) reduce LPL
mass and activity in culture medium [47].
A major question concerns the role of PPARs in the path-
ophysiology of atherosclerosis. Here we demonstrate that re-
duction in LPL secretion and activity leads to a reduced up-
take of glyLDL, a naturally occurring modi¢ed LDL particle
with high atherogenic potential. GlyLDL, which is elevated in
diabetes and hypercholesterolemia [48], can enhance chemo-
taxis and production of superoxide anions in macrophages
[48] and increase PAI-1 production [49] and prostaglandins
[50] in vascular endothelial cells. Thus, LDL glycation might
contribute to the increased risk of atherosclerosis in patients
with diabetes mellitus and familial hypercholesterolemia. Our
observations identify a novel bene¢cial role for PPAR in mac-
rophage cholesterol homeostasis, in addition to the previous
observation indicating that PPARK and PPARQ display anti-
atherogenic e¡ects via the induction of the reverse cholesterol
transport pathway in these cells [20].
In addition, the observed decrease of LPL activity could
lead to a reduced generation of triglyceride-rich lipoprotein
remnants which play a potentially atherogenic role at the
endothelium surface and intima of the arterial wall [51]. Tak-
en together our results demonstrate novel roles of PPARK
and PPARQ in lipoprotein metabolism in macrophages via
their actions on LPL expression and activity. Given the po-
tential pro-atherogenic e¡ect of macrophage LPL in the arte-
rial wall, these results could contribute to the bene¢cial e¡ects
of PPAR activators in atherosclerosis associated with diabe-
tes.
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